Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45

1.

Presynaptic control of striatal dopamine neurotransmission in adult vesicular monoamine transporter 2 (VMAT2) mutant mice.

Patel J, Mooslehner KA, Chan PM, Emson PC, Stamford JA.

J Neurochem. 2003 May;85(4):898-910.

2.

Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter.

Jones SR, Gainetdinov RR, Wightman RM, Caron MG.

J Neurosci. 1998 Mar 15;18(6):1979-86. Review.

3.

Substance P and cholecystokinin regulate neurochemical responses to cocaine and methamphetamine in the striatum.

Loonam TM, Noailles PA, Yu J, Zhu JP, Angulo JA.

Life Sci. 2003 Jun 27;73(6):727-39. Review.

PMID:
12801594
4.
5.

Dopamine transporters and neuronal injury.

Miller GW, Gainetdinov RR, Levey AI, Caron MG.

Trends Pharmacol Sci. 1999 Oct;20(10):424-9. Review.

PMID:
10498956
6.

The dopamine transporter: a vigilant border control for psychostimulant action.

Williams JM, Galli A.

Handb Exp Pharmacol. 2006;(175):215-32. Review.

PMID:
16722238
7.

Association of Stimulant Use With Dopaminergic Alterations in Users of Cocaine, Amphetamine, or Methamphetamine: A Systematic Review and Meta-analysis.

Ashok AH, Mizuno Y, Volkow ND, Howes OD.

JAMA Psychiatry. 2017 May 1;74(5):511-519. doi: 10.1001/jamapsychiatry.2017.0135. Review.

8.

Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease.

Lohr KM, Masoud ST, Salahpour A, Miller GW.

Eur J Neurosci. 2017 Jan;45(1):20-33. doi: 10.1111/ejn.13357. Epub 2016 Sep 2. Review.

PMID:
27520881
9.

Regulation of the Dopamine and Vesicular Monoamine Transporters: Pharmacological Targets and Implications for Disease.

German CL, Baladi MG, McFadden LM, Hanson GR, Fleckenstein AE.

Pharmacol Rev. 2015 Oct;67(4):1005-24. doi: 10.1124/pr.114.010397. Review.

10.

The vesicular monoamine transporter-2: an important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse.

Nickell JR, Siripurapu KB, Vartak A, Crooks PA, Dwoskin LP.

Adv Pharmacol. 2014;69:71-106. doi: 10.1016/B978-0-12-420118-7.00002-0. Review.

11.

VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse.

Eiden LE, Weihe E.

Ann N Y Acad Sci. 2011 Jan;1216:86-98. doi: 10.1111/j.1749-6632.2010.05906.x. Review.

12.

Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons.

Guillot TS, Miller GW.

Mol Neurobiol. 2009 Apr;39(2):149-70. doi: 10.1007/s12035-009-8059-y. Epub 2009 Mar 4. Review.

PMID:
19259829
13.

Presynaptic dopamine modulation by stimulant self-administration.

Espana RA, Jones SR.

Front Biosci (Schol Ed). 2013 Jan 1;5:261-76. Review.

14.

Pharmacological treatment with L-DOPA may reduce striatal dopamine transporter binding in in vivo imaging studies.

Nikolaus S, Antke C, Hautzel H, Mueller HW.

Nuklearmedizin. 2016;55(1):21-8. doi: 10.3413/Nukmed-0764-15-08. Epub 2015 Dec 7. Review.

PMID:
26642370
15.

Nonclassical pharmacology of the dopamine transporter: atypical inhibitors, allosteric modulators, and partial substrates.

Schmitt KC, Rothman RB, Reith ME.

J Pharmacol Exp Ther. 2013 Jul;346(1):2-10. doi: 10.1124/jpet.111.191056. Epub 2013 Apr 8. Review.

16.

Imaging the vesicular monoamine transporter.

Frey KA, Koeppe RA, Kilbourn MR.

Adv Neurol. 2001;86:237-47. Review.

PMID:
11553983
17.

Imaging studies on the role of dopamine in cocaine reinforcement and addiction in humans.

Volkow ND, Fowler JS, Wang GJ.

J Psychopharmacol. 1999 Dec;13(4):337-45. Review.

PMID:
10667609
18.

Genetic targeting of the amphetamine and methylphenidate-sensitive dopamine transporter: on the path to an animal model of attention-deficit hyperactivity disorder.

Mergy MA, Gowrishankar R, Davis GL, Jessen TN, Wright J, Stanwood GD, Hahn MK, Blakely RD.

Neurochem Int. 2014 Jul;73:56-70. doi: 10.1016/j.neuint.2013.11.009. Epub 2013 Dec 8. Review.

19.

How addictive drugs disrupt presynaptic dopamine neurotransmission.

Sulzer D.

Neuron. 2011 Feb 24;69(4):628-49. doi: 10.1016/j.neuron.2011.02.010. Review.

20.

Monoamine transporter as a target molecule for psychostimulants.

Sora I, Igari M, Yamamoto H, Ikeda K.

Nihon Yakurigaku Zasshi. 2007 Dec;130(6):450-4. doi: 10.1254/fpj.130.450. Review. Japanese. No abstract available.

PMID:
18079593

Supplemental Content

Support Center